Special Issue

Cannabinoids as Medicines

Message from the Guest Editor

The last three decades have seen real advances in the characterization of the body's endocannabinoid system, with detailed knowledge of cannabinoid receptor subtypes, endocannabinoid metabolic pathways and their cell signaling pathways. In parallel, advocacy, and some sanction, of the use of medicinal marijuana, often based on anecdotal evidence, has become a pertinent topic of societal and scientific debate. At a scientific level, interest has tended to shift away from use of $\Delta 9$ tetrahydrocannabinol (THC), due to its psychoactive intoxicant effects, towards alternative plant-derived phytocannabinoids or synthetic cannabinoids and their potential therapeutic applications. Despite some highprofile clinical failures, recent well-controlled clinical trials have begun to advance non-THC cannabinoids towards human therapeutic use. Authors are invited to submit original and review articles of basic science, preclinical and clinical findings contributing to the understanding of the current state of play and future potential for cannabinoids as medicines to be published in this Special Issue of Pharmaceuticals.

Guest Editor

Prof. Dr. Gary J. Stephens

School of Pharmacy, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UK

Deadline for manuscript submissions

closed (30 November 2018)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/11086

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

